Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,355 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,367)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04573231 | Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer | completed | Phase 2 | 13 | University of Wisconsin, MadisonOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05007106 | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Sep 28, 2026 | clinicaltrials |
| NCT02188745 | ER Reactivation Therapy for Breast Cancer(POLLY) | completed | Phase 2 | 20 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03568656 | Study to Evaluate CCS1477 in Advanced Tumours | completed | Phase 1 / Phase 2 | 219 | CellCentric Ltd.INDUSTRY | 6 | Sep 25, 2026 | clinicaltrials |
| NCT05498155 | Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer(OlympiaN) | completed | Phase 2 | 50 | AstraZenecaINDUSTRY | 9 | Sep 25, 2026 | clinicaltrials |
| NCT02860000 | Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer | completed | Phase 2 | 96 | Mayo ClinicOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05444998 | Neoadjuvant Inetetamab and Pyrotinib and Nab-paclitaxel for HER2+Breast Cancer | completed | Phase 2 | 20 | Xijing HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT00417495 | Sentinel Lymph Node Technique in Multifocal Breast Cancer(IGASSU) | completed | Phase 2 | 216 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT01658462 | Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer(VAROCE) | completed | Phase 2 | 51 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06033092 | Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion(TOLERANT) | completed | Phase 2 | 110 | European Institute of OncologyOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT03414684 | Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 78 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT01620359 | Study of ExAblate Focused Ultrasound Ablation of Breast Cancer | completed | Phase 2 | 14 | InSightecINDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04276493 | Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab | completed | Phase 1 / Phase 2 | 71 | BeiGeneINDUSTRY | 3 | Sep 2, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05150652 | Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer | completed | Phase 2 | 8 | Irada Ibrahim-zadaOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT02536742 | Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer(PYTHIA) | completed | Phase 2 | 124 | ETOP IBCSG Partners FoundationNETWORK | 3 | Aug 26, 2026 | clinicaltrials |
| NCT03644186 | To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)(TOUCH) | completed | Phase 2 | 147 | ETOP IBCSG Partners FoundationNETWORK | 4 | Aug 26, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05545150 | Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study | completed | Phase 2 | 113 | Northwestern UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05889728 | Pilot Trial to Assess 68Ga Bombesin PET/CT (NeoB) Imaging for Staging of Breast Cancer | completed | Phase 2 | 20 | St Vincent's Hospital, SydneyOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06685796 | A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer | completed | Phase 2 | 65 | BeBetter Med IncINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT02206984 | Endocrine Response in Women With Invasive Lobular Breast Cancer | completed | Phase 2 | 201 | Priscilla McAuliffeOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06375707 | First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer | completed | Phase 2 | 74 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT02654119 | Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery | completed | Phase 2 | 20 | University of NebraskaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06604858 | Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer(TELESCOPE) | completed | Phase 2 | 31 | MedSIROTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT02252887 | Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy | completed | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT02876302 | Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT04537286 | First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC Patients | completed | Phase 2 | 90 | Fudan UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04758780 | Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer(OPALESCENCE) | completed | Phase 2 | 12 | Institut Cancerologie de l'OuestOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04542135 | Sulindac and Breast Density in Women at Risk of Developing Breast Cancer | completed | Phase 2 | 61 | Alison StopeckOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06465368 | A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause | completed | Phase 2 | 121 | PfizerINDUSTRY | 13 | Jul 15, 2026 | clinicaltrials |
| NCT02364557 | Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival | completed | Phase 2 / Phase 3 | 129 | NRG OncologyOTHER | 4 | Jul 10, 2026 | clinicaltrials |
| NCT03180294 | Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer | completed | Phase 2 | 230 | NRG OncologyOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03671330 | Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. | completed | Phase 2 | 327 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT00317720 | Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT03179904 | TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer | completed | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07671547 | Prophylaxis of Hematologic Complications With Naderin in First-Line Breast Cancer Chemotherapy(NADERIN-BC) | completed | Phase 2 / Phase 3 | 79 | MIPO ClinicOTHER | 0 | Jun 30, 2026 | clinicaltrials |
| NCT00165256 | Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast | completed | Phase 2 | 157 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT00861705 | Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery | completed | Phase 2 | 454 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2026 | clinicaltrials |
| NCT01750073 | Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer | completed | Phase 2 | 92 | University of NebraskaOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03323346 | Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer(DISC) | completed | Phase 2 | 9 | The Institute of Molecular and Translational Medicine, Czech RepublicOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05185947 | Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07668076 | The Potential Cardioprotective Effect of Addition of Atorvastatin in Breast Cancer Patients | completed | Phase 2 | 44 | Damanhour UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05412446 | 99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes(99mTc-ADAPT6) | completed | Phase 2 | 30 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT03213041 | Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer | completed | Phase 2 | 12 | Northwestern UniversityOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT01730833 | Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer | completed | Phase 2 | 63 | City of Hope Medical CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04737265 | Pilot Study of an NTproBNP Guided Strategy of Cardioprotection(NTproBNP-Guide) | completed | Phase 1 / Phase 2 | 108 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT01556243 | Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer | completed | Phase 2 | 270 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06513364 | Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer | completed | Phase 2 | 40 | Beijing Wehand-Bio Pharmaceutical Co., LtdINDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
Data updated 24 hours agoSource updated Sep 28, 2026source: clinicaltrials